分享产品介绍 评论(0)
宿主来源
Human抗原名称
VEGF分子别名
Vascular endothelial growth factor A long form, L-VEGF, Vascular permeability factor (VPF), VEGFA细胞定位
SecretedAccession
P15692克隆号
S-SC020抗体类型
Recombinant mAb抗体同种型
IgG1,k纯化方式
Protein A浓度
2 mg/ml内毒素含量
<1EU/mg标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, containing no preservative
储存条件
12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用
Blocking of VEGF signaling Functional assays
稀释度
应用 稀释度 ELISA 1.221-5000 ng/ml
Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
ELISA
Immobilized VEGF-121 Protein, Human(UA040082) can bind Bevacizumab. The EC50 for this effect is 26.35 ng/mL.
评论(0)